Alyeska Investment Group L.P. Takes Position in GH Research PLC $GHRS

Key Points

• Alyeska Investment Group L.P. has made a new investment of approximately $5.02 million in GH Research PLC, acquiring 454,975 shares in the first quarter.
• GH Research has received mostly favorable ratings from analysts, with a current average rating of "Moderate Buy" and a target price of $32.00.
• The stock of GH Research PLC opened at $14.09 and has a market cap of $733.10 million, with a yearly trading range between $6.00 and $20.50.

Alyeska Investment Group L.P. purchased a new stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 454,975 shares of the company's stock, valued at approximately $5,018,000. Alyeska Investment Group L.P. owned about 0.87% of GH Research at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GHRS. BNP Paribas Financial Markets acquired a new stake in GH Research during the fourth quarter valued at approximately $44,000. Palumbo Wealth Management LLC bought a new position in shares of GH Research in the first quarter valued at $142,000. XTX Topco Ltd acquired a new stake in shares of GH Research during the 1st quarter valued at $169,000. Two Sigma Investments LP bought a new stake in shares of GH Research during the 4th quarter worth $117,000. Finally, Millennium Management LLC acquired a new stake in shares of GH Research during the fourth quarter worth $145,000. 56.90% of the stock is owned by institutional investors.

GH Research Stock Performance

Shares of NASDAQ GHRS traded down $0.61 during midday trading on Wednesday, reaching $12.81. 145,189 shares of the company traded hands, compared to its average volume of 325,547. The stock's 50-day simple moving average is $14.22 and its 200-day simple moving average is $12.11. GH Research PLC has a 12 month low of $6.00 and a 12 month high of $20.50. The firm has a market cap of $666.71 million, a PE ratio of -17.18 and a beta of 0.97.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. On average, equities research analysts expect that GH Research PLC will post -0.8 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Zacks Research lowered shares of GH Research from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Cantor Fitzgerald initiated coverage on shares of GH Research in a report on Wednesday, June 4th. They set an "overweight" rating and a $25.00 price target on the stock. Wall Street Zen raised shares of GH Research from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Finally, JMP Securities reiterated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a research report on Tuesday, June 24th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $32.00.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).